Not Yet RecruitingPhase 3

A Clinical Study of YK-1169 Versus Ceftazidime-Avibactam in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia

590 participantsStarted 2026-06-04

Plain-language summary

To evaluate the all-cause mortality rate at Day 28 in the YK-1169 group versus the ceftazidime-avibatan injection group in the mITT population.

Who can participate

Age range

18 Years – 75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

. Current or anticipated neutropenia, defined as \<500 neutrophils/mm³;
. Known human immunodeficiency virus (HIV) infection;
. Receipt of cancer chemotherapy, radiation therapy, or potent non-hormonal immunosuppressive agents (e.g., cyclosporine, azathioprine, tacrolimus, immunomodulatory monoclonal antibody therapies, etc.) within the past 3 months, or use of glucocorticoids equivalent to or exceeding 40 mg of prednisone daily for more than 14 days within the past 30 days

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Number of patients with all-cause mortality in the mITT population at Day 28

Timeframe: Day 28

Trial details

NCT IDNCT07634198

SponsorNanjing Yoko Biomedical Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-04-01

Contact for this trial

Zeya Jiao

86-15950520087 jiaozeya@yoko-bio.com

View on ClinicalTrials.gov More Hospital-acquired Bacterial Pneumonia (HABP) trials